Table 2. Cases studied in the present series.
| Western blot | ||||||
| Frontal cortex | Cerebellum | |||||
| Control (n = 15) | MM1 sCJD (n = 15) | VV2 sCJD (n = 15) | Control (n = 15) | MM1 sCJD (n = 15) | VV2 sCJD (n = 14) | |
| Gender (M/F) | 10/5 | 10/5 | 5/10 | 11/4 | 10/5 | 4/10 |
| Age (years)* | 60(15) | 68(9) | 61(11) | 62(12) | 66(15) | 63(11) |
| RT-qPCR | ||||||
| Frontal cortex | Cerebellum | |||||
| Control (n = 15) | MM1 sCJD (n = 15) | VV2 sCJD (n = 15) | Control (n = 15) | MM1 sCJD (n = 15) | VV2 sCJD (n = 10) | |
| Gender (M/F) | 10/5 | 10/5 | 5/10 | 10/5 | 10/5 | 4/6 |
| Age (years)* | 60(16) | 64(14) | 63(11) | 63(12) | 66(15) | 63(11) |
| Western blot | RT-qPCR | |||||
| Control (n = 14) | AD (n = 14) | LBD (n = 14) | Control (n = 15) | AD (n = 29) | LBD (n = 20) | |
| Gender (M/F) | 9/5 | 7/7 | 10/4 | 6/9 | 13/16 | 12/8 |
| Age (years)* | 69(12) | 74(6) | 71(10) | 70(12) | 78(7) | 72(11) |
| Control (n = 7) | PSP (n = 10) | FTLD (n = 10) | Control (n = 15) | PSP (n = 10) | FTLD (n = 10) | |
| Gender (M/F) | 4/3 | 4/6 | 4/6 | 9/6 | 4/6 | 4/6 |
| Age (years)* | 71(9) | 73(6) | 68(7) | 72(11) | 73(6) | 68(7) |
*Mean (SD). Control refers to cases with no neuropathological changes and cases with a few neurofibrillary tangles in the entorhinal and transentorhinal cortex (Braak stages I-II) if older than 62 y. sCJD, sporadic Creutzfeldt-Jakob disease (MM1 and VV2 subtypes); AD III-VI, Alzheimer disease stages III-VI according to Braak and Braak; LBD, Lewy body disease stages 3–6 of Braak; PSP, progressive supranuclear palsy; FTLD, frontotemporal lobar degeneration. FTLD included familial FTLD-tau due to mutations in the tau gene(fFTLD-tau) and FTLD-TDP-43 cases.